Maven Securities LTD Adma Biologics, Inc. Transaction History

Maven Securities LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.4 - $6.74 $220,000 - $337,000	50,000 New	50,000 $330,000
Q1 2023 May 15, 2023	BUY	$3.01 - $3.87 $150,500 - $193,500	50,000 New	50,000 $165,000
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $922,038 - $1.3 Million	-454,206 Reduced 96.8%	15,000 $365,000
Q2 2022 Aug 15, 2022	SELL	$1.43 - $2.2 $4.32 Million - $6.65 Million	-3,022,318 Reduced 86.56%	469,206 $929,000
Q1 2022 May 16, 2022	BUY	$1.28 - $1.83 $225,173 - $321,928	175,917 Added 5.31%	3,491,524 $6.39 Million
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.66 $3.61 Million - $5.5 Million	3,315,607 New	3,315,607 $4.68 Million
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.07 $1.13 Million - $1.55 Million	-750,325 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.67 - $2.95 $1.25 Million - $2.21 Million	750,325 New	750,325 $1.32 Million

319

185M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.91B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.